AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.

Equities research analysts at Zacks Research reduced their Q3 2024 earnings estimates for AbbVie in a research note issued on ...

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...

We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks. In this piece, we ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a ...

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.

On Thursday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $188.57 which represents a decrease of $-1.89 or -0.99% from the prior close of $190.46. The stock opened at $190.54 and touched a ...

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...

Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor ...

Failed to import article template. Reason: Failed to fetch dynamically imported module: ...